(Q35396369)

English

Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

immunohistochemistry

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Wang S

1

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Saboorian MH

2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Frenkel E

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Hynan L

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Gokaslan ST

5

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Ashfaq R

6

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

language of work or name

0 references

publication date

1 May 2000

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Journal of Clinical Pathology

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

374-381

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1731196

27 July 2018

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1731196

27 July 2018

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1731196

27 July 2018

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1731196

27 July 2018

HER-2/neu signal transduction in human breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1731196

27 July 2018

Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1731196

27 July 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1731196

27 July 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1731196

27 July 2018

Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1731196

27 July 2018

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1731196

27 July 2018

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1731196

27 July 2018

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1731196

27 July 2018

Clinicopathologic characteristics of replication error-positive gastric carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1731196

26 September 2018

Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1731196

26 September 2018

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10889820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased HER2 with U.S. Food and Drug Administration-approved antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/10889820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization

1 reference

https://pubmed.ncbi.nlm.nih.gov/10889820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10889820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10889820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/10889820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ERBB2 oncogene in human breast cancer and its clinical significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/10889820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

1 reference

https://pubmed.ncbi.nlm.nih.gov/10889820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/JCP.53.5.374

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35396369&oldid=1966908409"